Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alivation Research LLC

Neither a doctor nor a teaching hospital

Research payments

$3,438,534

535 payments

Through program year 2025, Alivation Research LLC is reported as receiving $3,438,534 in research payments, across 535 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $792,593 104
2024 Research $682,594 61
2023 Research $124,984 50
2022 Research $445,383 76
2021 Research $488,522 79
2020 Research $660,751 80
2019 Research $243,708 85

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sage Therapeutics, Inc. $869,631 76 payments
  2. ITI, Inc. $711,819 103 payments
  3. Sanofi Pasteur Inc. $496,435 32 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $441,589 14 payments
  5. Supernus Pharmaceuticals, Inc. $307,055 81 payments
  6. AbbVie, Inc. $191,064 19 payments
  7. Allergan Inc. $113,045 15 payments
  8. Neurocrine Biosciences, Inc. $95,189 77 payments
  9. Vanda Pharmaceuticals Inc. $73,196 2 payments
  10. Biohaven Pharmaceuticals, Inc. $34,258 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $508,889 56 payments
  2. Iti-007-321 $338,125 65 payments
  3. A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). $328,962 12 payments
  4. An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder $205,334 3 payments
  5. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $164,255 16 payments
  6. Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants $159,993 18 payments
  7. Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD $145,953 8 payments
  8. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $137,334 2 payments
  9. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00014 $95,419 1 payment
  10. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00014) $92,026 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record